Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.33
-8.1%
$0.40
$0.24
$2.53
$20.98M0.9791,629 shs492,189 shs
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.97
-3.0%
$0.96
$0.80
$2.18
$4.27M0.93386,808 shs40,246 shs
Rallybio Corporation stock logo
RLYB
Rallybio
$0.54
+15.1%
$0.39
$0.22
$1.30
$19.35M-1.178.41 million shs913,345 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.48
-3.9%
$1.31
$0.90
$1.96
$18.01M0.5294,197 shs38,062 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
-8.10%-6.99%-17.02%-40.86%-81.77%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-2.99%-5.82%+7.43%-3.87%-41.56%
Rallybio Corporation stock logo
RLYB
Rallybio
+15.05%+7.28%+65.69%+68.77%-61.51%
Synlogic, Inc. stock logo
SYBX
Synlogic
-3.90%-6.92%+22.82%+27.59%-12.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioAtla, Inc. stock logo
BCAB
BioAtla
2.0395 of 5 stars
3.31.00.00.02.22.50.6
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.1658 of 5 stars
0.02.00.00.00.61.70.0
Rallybio Corporation stock logo
RLYB
Rallybio
1.7774 of 5 stars
3.02.00.00.00.61.71.3
Synlogic, Inc. stock logo
SYBX
Synlogic
0.9696 of 5 stars
0.05.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.50
Moderate Buy$5.001,415.15% Upside
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
2.00
Hold$10.001,769.16% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M1.75N/AN/A$0.25 per share1.32
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$0.73 per shareN/A
Rallybio Corporation stock logo
RLYB
Rallybio
$848K26.25N/AN/A$1.49 per share0.36
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,731.60N/AN/A$1.09 per share1.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$5.26M-$1.10N/AN/AN/A-164.79%-71.12%9/15/2025 (Estimated)
Rallybio Corporation stock logo
RLYB
Rallybio
-$57.78M-$1.09N/AN/AN/A-5,682.19%-72.31%-64.78%8/14/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)

Latest CMND, BCAB, SYBX, and RLYB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.29N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.13N/AN/AN/AN/AN/A
6/12/2025Q2 2025
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.16N/A-$0.16N/AN/A
5/8/2025Q1 2025
Rallybio Corporation stock logo
RLYB
Rallybio
-$0.21-$0.21N/A-$0.21N/A$0.21 million
5/6/2025Q1 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.28-$0.29-$0.01-$0.26N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Rallybio Corporation stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
2.35
2.35
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
1.74
1.74
Rallybio Corporation stock logo
RLYB
Rallybio
N/A
14.68
14.68
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Rallybio Corporation stock logo
RLYB
Rallybio
90.34%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
11.50%
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
Rallybio Corporation stock logo
RLYB
Rallybio
8.70%
Synlogic, Inc. stock logo
SYBX
Synlogic
3.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.42 million51.70 millionOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A4.27 millionN/ANot Optionable
Rallybio Corporation stock logo
RLYB
Rallybio
4041.61 million37.99 millionNot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable

Recent News About These Companies

Synlogic Reports Q3 2024 Financial Outcomes
Synlogic Reports Third Quarter 2024 Financial Results
Synlogic, Inc. (0A8U.L)
MIN.SG,0P0001I7V6,0 (MIN.SG)
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
Synlogic Reports Second Quarter 2024 Financial Results
Synlogic Inc.
Synlogic Inc SYBX
Synlogic Flat on Q1 Numbers
Synlogic Reports First Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.33 -0.03 (-8.10%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.34 +0.01 (+2.73%)
As of 08/1/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$0.97 -0.03 (-2.99%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.97 +0.00 (+0.09%)
As of 08/1/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.54 +0.07 (+15.05%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.53 -0.01 (-1.31%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.48 -0.06 (-3.90%)
Closing price 08/1/2025 03:50 PM Eastern
Extended Trading
$1.50 +0.02 (+1.69%)
As of 08/1/2025 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.